Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with high mortality and poor outcome, especially for elderly/unfit (age ≥ 60 years or unfit patients who are ineligible to receive intensive chemotherapy) with adverse genetic and molecular abnormalities in the newly diagnosed (ND) and refractory/relapsed (R/R) patients.
Azacitidine (Aza), a hypomethylating agent, targets epigenetic gene silencing by inhibiting gene expression against malignant phenotypes. The complete remission (CR) rates of Aza combined regimens varied with different drugs, such as, Aza+Midostaurin (20.8%), Aza+Durvalumab (31.3%), Aza+Pracinostat (46%), Aza+Venetoclax (66.4%) in ND AML and Aza+Midostaurin (21.4%), Aza+Nivolumab (22%), Aza+Venetoclax (37.1%) in R/R AML [1,2,3,4,5,6,7].
Homoharringtonine (HHT) is a natural plant alkaloid isolated from Cephalotaxus and exhibits an anti-leukemic effect [8, 9]. Several studies revealed that HHT- combined regimens are effective and safe in patients with chronic myeloid leukemia of ND or failed prior therapy (imatinib, IFNa) [10,11,12,13]. It is reported that HHT in combination with cytarabine, aclarubicin/daunorubicin (HAA/HDA) achieved a higher CR than the standard “3 + 7” regimen (DA) in treating de novo AML . HAG (HHT, low-dose cytarabine, G-CSF), which is called a priming regimen, was preferred to treat the elderly/unfit AML due to its low cardiac toxicity and well-tolerance. However, so far, it has not been well determined the efficacy and safety of adding Aza to the HAG regimen.
This is a multicenter, single-arm, phase 2 clinical trial done in 17 institutions in China. The trial was registered on ClinicalTrials.gov (NCT04248595). This study was approved by IEC for Clinical Research of Zhongda Hospital, Affiliated to Southeast University (2019ZDSYLL211-P01) and all patients provided written informed consent. Inclusion criteria were: 1) confirmed diagnosis of AML by the WHO criteria. 2) age ≥ 60 years or unfit patients who are ineligible to receive intensive chemotherapy who had at least one of the following coexisting conditions:  a history of congestive heart failure with an ejection fraction of 50% or less, or chronic stable angina  chronic respiratory disease with forced expiratory volume less than 65% in 1 s , Eastern Cooperative Oncology Group (ECOG) score of 2 or 3. 3) aspartate and alanine aminotransferase concentrations < 2 times the upper limit of normal, serum bilirubin concentration ≤ 35 μmol/L. 4) able to understand and provide written consent. Exclusion criteria were: 1) confirmed diagnosis of acute promyelocytic leukemia. 2) < 18 years. 3) co-existence with other non-hematological neoplasms. 4) infection of HIV. 5) lactating or pregnant women. 6) other medical or psychological diseases which investigators believed were not suitable to enter the trial.
A total of 112 patients [median age 65 (24–86) years)] were enrolled between Jan 2020 and Dec 2021, including 72 ND and 40 R/R (Fig. S1A). The 72 ND AML comprise 56 de novo AML [no history of myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), or exposure to potentially leukemogenic agents] and 16 secondary AML (s-AML, arising from preexisting myeloid neoplasms). Among them, 33 patients aged < 60 years were recruited according to the unfit criteria (Table S1). The risk categories of the 72 ND AML patients were classified into favorable-risk (19/72), intermediate-risk (31/72), and poor-risk (22/72).
Induction therapy consisted of Aza (75 mg/m2/d on days 1–7 subcutaneous) was given in combination with the HAG regimen [HHT 1 mg/m²/d on days 4–17 intravenous over 3 h, cytarabine 10 mg/m² every 12 h on days 4–17 subcutaneous, and G-CSF 200 μg/m²/d subcutaneous from day 4 until WBC > 10 × 109/L(14-day HAG schedule) (38/112 patients); HHT 1 mg/m²/d on days 4–10 intravenous over 3 h, cytarabine 10 mg/m² every 12 h on days 4–10 subcutaneous, and G-CSF 200 μg/m²/d subcutaneous from day 4 until WBC > 10 × 109/L(7-day HAG schedule) (74/112 patients)]. Patients who did not achieve CR/CRi (CR with incomplete blood count recovery) following the first cycle could receive a second cycle at the same doses and schedule. The patients who did not reach CR/CRi after the second cycle were withdrawn from the study. Post-remission therapy for enrolled patients, the Aza+HAG regimen was further given 4–6 cycles or until the disease progresses, two of whom underwent allo-SCT (one was 55 years with sAML from MDS, the other was 41 years with relapsed AML).
The detailed procedures, clinical endpoint, and assessments are in online supplemental methods. The gene mutations were screened in 103 patients using the targeted leukemia exome-seq panel including 58 genes. The detailed panel design, screening, data analysis; association of gene mutations with clinical responses, relapse status, risk groups, and other statistics are described in the online supplemental methods.
Of 112 patients, 73 (65.2%) achieved CR/CRi within the median time of 33.5d. Notably, 90.4% (66/73) of CR/CRi was obtained after the 1st cycle of Aza+HAG induction therapy. No statistical difference in CR/CRi rate between Aza+HAG (7-day) (62.2%, 46/74) vs Aza+HAG (14-day) (71.1%, 27/38) (P = 0.35). A higher CR/CRi rate of 79.2% in ND AML compared with 40.0% in R/R AML; and sAML (75.0%) obtained a similar high CR rate as de novo AML (80.4%) (Fig. 1A). In patients with favorable, intermediate or poor risk, the CR/CRi rate were 94.7%, 83.9%, and 59.1%, respectively (Fig. 1B). These data indicated that Aza+HAG regimen has high efficacy not only for ND de novo AML with favorable-intermediate risk, but also for elderly/unfit patients with sAML, poor-risk, and R/R AML.
The median overall survival (OS) and relapse-free survival (RFS) in ND AML were 22.8 m and not reached, respectively, which were longer than R/R AML (median OS 10.8 m, P = 0.0056; median RFS 5.21 m, P = 0.0051) (Fig. 1C, D). De novo AML had a superior median OS (22.8 m) and RFS (not reached) compared with sAML (median OS 11.3 m, P = 0.01; median RFS 5.61 m, P = 0.0048) (Fig. S1B, C). In patients with favorable, intermediate, or poor risk, median OS was not reached, 22.8 m, and 17.3 m (Fig. 1E); median RFS was not reached, 16.9 m, and not reached (Fig. 1F), respectively. These data suggested that better survival could be achieved with the Aza+HAG regimen, especially for elderly/unfit patients with ND de novo AML.
We further compared the efficacy of the Aza+HAG vs HAG regimen in our center (Zhongda Hospital). The baseline demographic and characteristics were generally balanced between the two cohorts (Table S2). The CR/CRi rate with the Aza+HAG regimen (80.0%) is significantly higher than that of the HAG control (42.9%) (P = 0.016) (Fig. 1G). The median OS and RFS with the Aza+HAG regimen were significantly longer than HAG control (12.6 m vs 5.57 m, P = 0.0294; 8.82 m vs 3.50 m, P = 0.0472), respectively (Fig. 1H, I). We also performed a meta-analysis including 453 elderly/unfit AML patients from 17 previous reported HAG studies and the estimated CR/CRi rate was 47.0% (Fig. 1J and S2). These data indicated that adding Aza to the HAG increases the clinical responses and outcomes for elderly/unfit AML.
The most common non-hematological adverse event (AE) was infection (58.0%). Common non-hematological AEs of grade 3 or higher includes: infection (33.9%), hemorrhage (9.82%), fatigue (5.36%), hypokalemia (3.57%), cardiac arrhythmia (1.79%), and fever (1.79%). For the hematological AE, the median duration of neutropenia and thrombocytopenia were 11 d (IQR, 7–19d) and 16d (IQR, 11–25d), 10 d (IQR, 6.25–18d), and 16 d (IQR, 10.25–24.75d), 12d (IQR, 8–21d) and 17d (IQR, 12–27d) for total, 7-day, and 14-day schedule, respectively. No differences were observed between the 7-day and 14-day schedule. The early deaths within 4 weeks of the induction treatment occurred in 1.79%. No patients discontinued the induction therapy due to hematological or non-hematological toxicities (Table S3). These data indicated that HHT had much lower cardiac toxicity and hematological suppression compared with daunorubicin in the standard regimen.
We detected 228 mutants involving 33 genes in 103 patients. The median mutation number per patient was 2.21 (range, 0–7) and 87.4% (90/103) of patients had more than one gene mutation. The most frequently mutated genes were DNMT3A, TET2, and NPM1 (Fig. 2A). We observed the high CR/CRi rate in ND patients with mutated BCOR (100%,7/7), KIT (100%,3/3), IDH1 (100%,7/7), NPM1 (93.3%,14/15), ASXL1 (88.9%,8/9), DNMT3A (80. 0%,16/20), RUNX1 (75.0%,6/8), FLT3 (71.4%,5/7) and TET2 (71.4%,10/14) (Fig. 2B) (Table S4). We also found the variant allele fraction (VAF) of mutants was dramatically reduced (<0.01%), particularly with mutations of FLT3, IDH1, ASXL1, and NPM1 (Fig. 2C-F). OS and RFS in patients with FLT3 or ASXL1 mutation showed no inferior tendency, compared with those without FLT3 or ASXL1 mutation (Fig. S3A-D); whereas patients with IDH1 mutation showed a better tendency in RFS, compared with patients with IDH1 wild type (Fig. S3E, F). These data suggested that this scheme could overcome the poor prognosis associated with unfavorable molecular abnormalities.
Recent studies reported the CR rates of patients treated with the Aza plus IDH1 inhibitor Ivosidenib (60.9%)  in IDH1-mutant ND AML or HMA + Venetoclax (71%) in IDH1/2-mutant AML . This trial showed a high CR/CRi rate of 100% in the IDH1-mutant AML and the IDH1 mutant was dramatically reduced after the first cycle of Aza+HAG, suggesting that the patients with the IDH1 mutation could achieve a remarkable deep and durable remission upon Aza+HAG treatment.
In summary, this trial demonstrated that the Aza+HAG regimen is a cost-effective first-line therapy with high efficacy and well tolerance for elderly/unfit AML. This trial provides a rationale for further expanding the patients for randomized clinical controlled studies and guiding suggestions for the clinical use of this novel combination therapy.
All data generated or analyzed during this study are included in this published article.
Tomlinson BK, Gallogly MM, Kane DM, Metheny L, Lazarus HM, William BM, et al. A phase II study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:226–33.e1.
Zeidan AM, Boss I, Beach C, Copeland WB, Thompson E, Fox BA, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6:2219–29.
Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3:508–18.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617–29.
Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, William WT, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015;15:428–32.e2.
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyAzacitidine and Nivolumab in Relapsed AML. Cancer Disco. 2019;9:370–83.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5:1552–64.
Jin J, Wang J-X, Chen F-F, Wu D-P, Hu J, Zhou J-F, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukemia: a multicentre, open-label, randomized, controlled phase 3 trial. Lancet Oncol. 2013;14:599–608.
Legha S, Keating M, Picket S, Ajani J, Ewer M, Bodey G. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984;68:1085–91.
Quintás‐Cardama A, Kantarjian H, Garcia‐Manero G, O’Brien S, Faderl S, Estrov Z, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248–55.
Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18:3513–21.
O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, et al. Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98:888–93.
O’Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, et al. Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia. Cancer 2002;94:2024–32.
DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2020;39:57–65.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133:7–17.
This work is supported in part by The National Natural Science Foundation of China (82070166); Jiangsu Province “333” project (BRA2019103); Medical research key projects-Jiangsu Commission of Health (ZD2021003); The Fundamental Research Funds for the Central Universities-the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX22_0296, KYCX20_0147); Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology (2017).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, J., Han, Q., Huang, Y. et al. High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study. Blood Cancer J. 12, 145 (2022). https://doi.org/10.1038/s41408-022-00740-3